ANIP (ANI Pharmaceuticals) חוב לטווח קצר להון

The debt-to-equity ratio for ANI Pharmaceuticals (ANIP) is 0.12. Stability in these metrics is supported by the absence of external sanctions and the localization of resources to combat raw material shortages. Business development relies on the creation of automated lines for complex liquid dosage forms. The company's success is based on patent protection and the efficient procurement of authorizations for the production of both branded and generic medicines.

Steady demand for niche drugs from ANI Pharmaceuticals (ANIP) minimizes dependence on market cycles, which is reflected in the moderate dynamics of short-term debt levels. This ratio compares liabilities with a maturity of up to one year against total capital, allowing investors to quickly assess current liquidity and the risk of excessive debt leverage that could limit the pace of business expansion.